A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

← catalyst calendar

NCT07623187 · readout in 1,746 d

Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.

Phase

Phase 2/3

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

450estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-11-01

estimated

When the study began enrolling

Primary completion

2031-05-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2032-05-31

estimated

The whole study's end, after follow-up

First posted

2026-06-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Acute Myeloid Leukaemia (AML)
Acute Myeloid Leukaemia

Interventions

Biological: IPN60340 + azacitidine + venetoclax — also filed as ICT01
Drug: Placebo + azacitidine + venetoclax — also filed as NaCl

Primary outcome

what the primary-completion date above is the date OF

(Phase 2b and Phase 3) Percentage of participants with Complete Remission (CR)

measured From randomization to end of Cycle 6 (approximately 6 months)

Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed